课题基金 / 基金详情

90Y0CC49 MONOCLONAL ANTIBODY IN ADVANCED NON SMALL CELL LUNG CANCER

90Y0CC49 MONOCLONAL ANTIBODY IN ADVANCED NON SMALL CELL LUNG CANCER
90Y0CC49 单克隆抗体治疗晚期非小细胞肺癌
批准号：
6244030
负责人：
FRANCISCO ROBERT
金额：
$2.46万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-10 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244030
关键词：
clinical research clinical trial phase I combination cancer therapy combination chemotherapy dosage drug adverse effect drug screening /evaluation ethylenediaminetetraacetate human subject human therapy evaluation immunotherapy interferon alpha monoclonal antibody neoplasm /cancer chemotherapy nonsmall cell lung cancer pharmacokinetics

项目摘要

项目成果

FRANCISCO ROBERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
A phase I study to determine the maximum tolerated dose (MTD) of 90Y- CC49 monoclonal antibody with alpha-interferon in patients with advanced non-small cell lung cancer. Other objectives include pharmacokinetic analysis on 90Y-CC49 with or without concomitant EDTA/DPTA, biodistribution and tumor targeting data with 111IN-CC49, and to evaluate the safety and efficacy of concomitant chelator therapy (EDTA or DPTA) to increase the MTD for 90Y-CC49.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
海外基金